V3 loop characterization by ultradeep sequencing during CCR5 antagonist therapy

CCR5 拮抗剂治疗期间通过超深测序表征 V3 环

• 批准号: 7419394
• 负责人: Daniel R. Kuritzkes
• 金额: $ 26.6万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-19 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7419394
• 关键词: AIDS clinical trial group; Amino Acid Substitution; Anti-Retroviral Agents; Binding; Biological Assay; Biological Sciences; CCR5 gene; CXCR4 gene; Cell Surface Receptors; Cells; Clinical; Clinical Trials; Data; Disease; Disease Progression; Emulsions; Enrollment; Evolution; Failure; Generations; Genotype; HIV Envelope Protein gp120; HIV Infections; HIV-1; Heterogeneity; Immune; In Vitro; Membrane Fusion; Methods; Minor; Minority; Nature; Nucleotides; Pathogenesis; Patients; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phylogenetic Analysis; Plasma; Play; Population; Population Dynamics; Positioning Attribute; Process; RNA; Research; Resistance; Role; Sampling; Speed; Structure; System; Techniques; Technology; Therapeutic; Time; Toxic effect; Trees; Tropism; V3 Loop; Variant; Viral; Viral Envelope Proteins; Virus; advanced disease; chemokine receptor; density; drug resistant virus; experience; improved; in vivo; inhibitor/antagonist; molecular rearrangement; neutralizing antibody; new technology; novel; pressure; receptor; response; small molecule

DESCRIPTION (provided by applicant): In an effort to provide additional therapeutic options to patients with drug resistant virus or untoward toxicities on existing therapy, new drugs with potent antiretroviral activity are being developed that target and block HIV-1 entry into cells. Vicriviroc (VCV) is an investigational second-generation CCR5 (R5) antagonist that demonstrated potent and selective inhibition of HIV-1 in vitro and demonstrated potent virologic suppression through 24 weeks in HIV-1-infected treatment-experienced subjects enrolled in A5211, a phase IIb clinical trial. Subjects enrolled in clinical trials of vicriviroc and maraviroc have been identified with changes in viral co-receptor usage that emerge during therapy. The composition of the viral quasispecies is especially relevant during treatment with R5 inhibitors because there is legitimate concern that antagonism of CCR5 will result in viral adaptation, emergence of a dominant CXCR4 (X4)-using virus, and worsening of clinical disease. The characterization of the specific nature of CXCR4-using variants that develop in vivo and an accurate description of the viral quasispecies that emerge during therapy are hampered by current technological limitations. The purpose of this proposal is to assess the feasibility of using a novel ultra-deep sequencing technology to track dynamic shifts in the viral quasispecies in response to treatment with vicriviroc. Using subject samples from ACTG 5211, we will apply this technology to the sequencing of the V3 loop of gp120, a major determinant of co-receptor usage from subjects who have experienced changes in coreceptor usage on vicriviroc. We will investigate the emergence of CXCR4-using variants on R5 antagonist therapy and more accurately determine the origin of these viruses - either de novo emergence or expansion of a pre-existing minority X4 population. We hypothesize that the use of this highly parallel sequencing system will dramatically improve the speed and depth of sequencing and, for the first time, permit a comprehensive identification of minority viral populations that would not be possible using currently available techniques. More specifically, we propose to: sequence the V3 loop of gp120 from subjects experiencing tropism shifts using the highly parallel 454 sequencing system, investigate shifts in the proportion of CXCR4-using quasispecies variants in response to vicriviroc treatment, and determine the evolutionary origins and population dynamics of V3 loop sequences during vicriviroc treatment. Changes in HIV-1 envelope and the transition from R5 to X4 viruses even in the absence of drug therapy are important factors in pathogenesis and disease progression. The proposed studies will provide an unprecedented wealth of sequence data to illuminate the effects of CCR5 antagonist therapy on viral coreceptor usage and V3 loop sequence evolution across the entire quasispecies within an infected host. These studies will contribute to a better understanding of the role these changes may play in disease pathogenesis.

描述（由申请人提供）：为了给现有治疗中存在耐药病毒或不良毒性的患者提供额外的治疗选择，正在开发具有强效抗逆转录病毒活性的新药，这些药物靶向并阻断HIV-1进入细胞。Vicriviroc（VCV）是一种研究性第二代CCR 5（R5）拮抗剂，在体外表现出对HIV-1的强效和选择性抑制作用，并在入组A5211（IIb期临床试验）的HIV-1感染治疗受试者中表现出24周的强效病毒学抑制作用。已确定入组vicriviroc和maraviroc临床试验的受试者在治疗期间出现病毒辅助受体使用的变化。在R5抑制剂治疗期间，病毒准种的组成尤其相关，因为存在合理的担忧，即CCR 5的拮抗作用将导致病毒适应、出现优势CXCR 4（X4）使用病毒和临床疾病恶化。目前的技术限制阻碍了体内开发的CXCR 4使用变体的特定性质的表征和治疗期间出现的病毒准种的准确描述。本提案的目的是评估使用新型超深度测序技术跟踪病毒准种对vicriviroc治疗的动态变化的可行性。使用ACTG 5211的受试者样本，我们将应用该技术对gp 120的V3环进行测序，这是vicriviroc治疗后辅助受体使用发生变化的受试者中辅助受体使用的主要决定因素。我们将研究CXCR 4的出现-使用R5拮抗剂治疗的变体，并更准确地确定这些病毒的起源-从头出现或预先存在的少数X4群体的扩展。我们假设，使用这种高度平行的测序系统将大大提高测序的速度和深度，并首次允许全面鉴定少数病毒群体，这是使用目前可用的技术不可能实现的。更具体地说，我们建议：使用高度平行的454测序系统对经历向性变化的受试者的gp 120的V3环进行测序，研究响应于vicriviroc治疗的使用准种变体的CXCR 4比例的变化，并确定vicriviroc治疗期间V3环序列的进化起源和群体动力学。HIV-1包膜的变化和从R5到X4病毒的转变，即使在没有药物治疗的情况下，也是发病机制和疾病进展的重要因素。拟议的研究将提供前所未有的丰富的序列数据，以阐明CCR 5拮抗剂治疗对感染宿主内整个准种的病毒辅助受体使用和V3环序列进化的影响。这些研究将有助于更好地了解这些变化在疾病发病机制中可能发挥的作用。